In previous post hoc analyses of the WISDOM (Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management) study in patients with severe COPD on dual bronchodilation using the 9-month treatment interval after ICSs had been withdrawn, eosinophil thresholds of 300 and 400 cells/ml (approximately 20 and 11% of the overall WISDOM population, respectively) identified patients with more exacerbations after withdrawal of ICS (5). A negative binomial regression model was used to estimate the moderate or severe exacerbation rate ratio over the 9 months after complete withdrawal of ICSs. ...although the greater than or equal to 400 cells/ml threshold provides the greatest confidence that patients will benefit from ICSs, our data indicate that patients with eosinophil counts between 300 and 400 cells/ml will also benefit from additional ICS treatment. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary.